Forian Inc(FORA) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.16 | Insider Own | 70.69% | Shs Outstand | 31.2M | Perf Week | - |
| Market Cap | 0.07B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 9.2M | Perf Month | 0.93% |
| Enterprise Value | 0.04B | PEG | - | EPS next Q | - | Inst Own | 9.69% | Short Float | 0.14% | Perf Quarter | 3.83% |
| Income | -0.01B | P/S | 2.26 | EPS this Y | - | Inst Trans | -1.22% | Short Ratio | 0.43 | Perf Half Y | 0.93% |
| Sales | 0.03B | P/B | 2.52 | EPS next 5Y | - | ROA | -11.69% | Short Interest | 0.01M | Perf YTD | 2.36% |
| Book/sh | 0.86 | P/C | 2.19 | EPS past 3/5Y | 51.54% 11.16% | ROE | -17.95% | 52W High | -19.93% ($2.71) | Perf Year | 16.67% |
| Cash/sh | 0.99 | P/FCF | - | Sales past 3/5Y | 22.6% 123.31% | ROIC | -19.01% | 52W Low | 32.32% ($1.64) | Perf 3Y | -9.21% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -38.77% | Gross Margin | 46.5% | Volatility(W/M) | 0.59% 0.5% | Perf 5Y | -76.89% |
| Dividend TTM | - | EV/Sales | 1.23 | Sales Y/Y TTM | 34.57% | Oper. Margin | -13.34% | ATR (14) | 0.01 | Perf 10Y | -72.87% |
| Dividend Ex-Date | - | Quick Ratio | 3.04 | EPS Q/Q | -198.07% | Profit Margin | -17% | RSI (14) | 63.98 | Recom | 3 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.04 | Sales Q/Q | -2.91% | SMA20 | 0.67% ($2.16) | Beta | 0.92 | Target Price | $2.1 |
| Payout | - | Debt/Eq | 0 | Earnings | 2025/11/06 | SMA50 | 2.55% ($2.12) | Rel Volume | 0 | Prev Close | $2.17 |
| Employees | 50 | LT Debt/Eq | 0 | EPS/Sales Surpr. | -100% 6.86% | SMA200 | 2.16% ($2.12) | Avg Volume(3M) | 0.03M | Price | $2.17 |
| IPO | 2007/8/20 | Option/Short | Yes/No | Trades | 0 | Volume | - | Change | - |
📊 A U.S. data technology company that delivers business insights to pharmaceutical companies and financial institutions through healthcare big data analytics and artificial intelligence (AI) solutions. Leveraging its proprietary 'Chronos™' data lake, the company is a leader in precision medicine and market analytics services.
Over the past 1 year, roughly in the middle
20% below its 1-year high.
Traded less than usual. That is 0% of its average volume.
FORA has a sound balance sheet but weak earning power
Of every $100 in sales, $13.34 is lost.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $226. Peers typically go for $77.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Hold.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -76.9%. The S&P 500 did +55% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 9.7%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #31 of 41 in the industry
Based on market cap of $68M.
FAQ
What kind of company is FORA?
FORA belongs to the Healthcare sector and operates in the Health Information Services industry.
What is the market cap of FORA?
The market cap of FORA is approximately $68M, ranking 4,794 within its sector.
What is the 52-week high and low for FORA?
FORA has recorded a 52-week high of $2.71 and a low of $1.64.